Evidence map›Paper›PMID 41446536›Full record

ArticleHemaSphere2025

MMS22L is a novel key actor of normal and pathological erythropoiesis.

Elia Colin, Ivan Ferrer-Vicens, Dror Brook, Mohammad Salma, Charlotte Andrieu-Soler, Elisa Bayard, Alicia Fernandes, Chantal Brouzes, Carine Lefèvre, Romain Duval and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Histone Nuclear Import and Beyond: Multifunctional Roles of Importins.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Elia ColinLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute Université Paris Cité Paris France.ORCID https://orcid.org/0000-0002-6673-984X
Ivan Ferrer-VicensSchool of Biochemistry University of Bristol Bristol United Kingdom.
Dror BrookDepartment of Applied Math and Computer Science Weizmann Institute of Science Rehovot Israel.ORCID https://orcid.org/0000-0003-3276-9941
Mohammad SalmaInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Charlotte Andrieu-SolerInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Elisa BayardLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute Université Paris Cité Paris France.
Alicia FernandesVVTG platform, SFR Necker Paris France.
Chantal BrouzesLaboratory of Onco-Hematology, Necker Children's Hospital Assistance Publique-Hôpitaux de Paris (APHP) Paris France.
Carine LefèvreInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Romain DuvalUniversité Paris Cité and Université des Antilles, INSERM, Unité Mixte de Recherche (UMR)-S1134, Laboratory of Blood Group Antigens, Hematopoiesis and Sickle Cell Disease, Paris, France 2Centre National de Référence pour les Groupes Sanguins Établissement Français du Sang Ile-de-France Paris France.
Michaël DussiotLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute Université Paris Cité Paris France.
Thiago TrovatiLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute Université Paris Cité Paris France.
Geneviève CourtoisLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute Université Paris Cité Paris France.
Slim AzouziInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Mohammed ZarhrateGenomics Core Facility, Institut Imagine-Structure Fédérative de Recherche Necker, INSERM U1163 et INSERM US24/CNRS UMS3633 Paris Descartes Sorbonne Paris Cite University Paris France.
Anne LambilliottePediatric Hematology Lille University Hospital Lille France.
Sophie ParkInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, CS 10217, 38043, CHU Grenoble University of Grenoble Alpes Grenoble France.
Benjamin CarpentierHematology Department, Saint Vincent de Paul Hospital Lille Catholic University Lille France.
Martin ColardLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute Université Paris Cité Paris France.
Sandra ManceauInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Despina MoshousDepartment of Pediatric Immunology, Hematology and Rheumatology, Necker Children's Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Laboratory "Genome Dynamics in the Immune System", INSERM UMR1163 Université Paris Cité, Institut Imagine Paris France.
Patrick MayeuxInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Emilie-Fleur GautierInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Annarita MiccioLaboratory of chromatin and gene regulation during development, INSERM U1163, Imagine Institute Université Paris Cité Paris France.
Jean SoulierHematology Laboratory, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris (APHP), INSERM U944/CNRS UMR7212, Saint Louis Research Institute Université Paris Cité Paris France.
William VainchenkerInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Liran ShlushDepartment of Molecular Cell Biology Weizmann Institute of Science Rehovot Israel.
Lydie Da CostaInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Jan FrayneSchool of Biochemistry University of Bristol Bristol United Kingdom.
Eric SolerInitiatives IdEx Globule Rouge d'Excellence (Inidex GR-Ex) Université Paris Cité Paris France.
Olivier HermineLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute Université Paris Cité Paris France.
Lucile CouronnéLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute Université Paris Cité Paris France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of next-generation sequencing techniques has led to the genetic characterization of numerous congenital erythroid disorders, emphasizing crucial pathways in both normal and pathological erythropoiesis. In this study, whole exome sequencing of a single patient with atypical congenital pure red cell aplasia revealed a mutation in the

Identifiers

PMID41446536
PMCPMC12723439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.